Clinical Breast Cancer
IF
2.65
Papers
1933
Papers 2167
1 page of 217 pages (2,167 results)
Newest
#1Aileen Zeng (USYD: University of Sydney)
#2Meagan Brennan (USYD: University of Sydney)H-Index: 20
Last. Nehmat Houssami (USYD: University of Sydney)H-Index: 72
view all 5 authors...
Abstract null null Background null Supplemental screening with MRI or ultrasound increases cancer detection rate (CDR) in women with standard screening mammography. Whether it also reduces interval cancer rate (ICR) is unclear. This study reviewed the evidence evaluating the effect of supplemental imaging on ICR in women undergoing screening mammography. null null null Materials and Methods null This systematic review included studies that reported both CDR and ICR in women undergoing screening ...
Source
#1Louise Benoit (Curie Institute)H-Index: 3
#2Carine Cambra (Curie Institute)
Last. Claire Bonneau (Université Paris-Saclay)H-Index: 12
view all 7 authors...
Abstract null null Objective null : The objective of our study was to analyse quality of life (QOL) in an e-cohort of patients treated for breast cancer (BC) by endocrine therapy (ET), by means of validated quality of life questionnaires. null null null Study design and setting null : A retrospective, observational, e-cohort study was conducted (Seintinelles platform). Female patients treated for non-metastatic and non-recurrent BC, treated in France after 2005, filled in online questionnaires c...
Source
#1Huiqing Jia (Qingdao University)
#2Yan Zheng (Qingdao University)
Last. Chengqin Wang (Qingdao University)H-Index: 5
view all 7 authors...
Abstract null null Objective null To investigate the clinicopathologic characteristics and outcome of bilateral breast cancer (BBC) in the Chinese population. null null null Methods null : A retrospective study was conducted on 7797 cases with primary breast cancer diagnosed between 2016 and 2020, including 7618 cases of unilateral breast cancer (UBC) and 179 cases of BBC. Among the latter, there were 108 cases of synchronous BBC (SBBC) and 71 cases of metachronous BBC (MBBC). We compared the cl...
Source
#1Sara De Matteis (Sapienza University of Rome)H-Index: 25
#2Giuseppe Facondo (Sapienza University of Rome)H-Index: 1
Last. Mattia Falchetto Osti (Sapienza University of Rome)H-Index: 25
view all 9 authors...
Aim null To evaluate the efficacy and safety of hypofractionated radiation therapy (HFRT) of the breast/chest wall and regional nodes in patients with locally advanced breast cancer and positive lymph nodes. null Materials and methods null One hundred and twenty-two patients treated between October 2016 and March 2020 with HFRT were retrospectively reviewed. A total dose of 42.4 Gy was delivered to the chest wall and lymph nodes in 16 fractions of 2.65 Gy each, using the IMRT technique. Patients...
1 CitationsSource
#1Lindsey Jung (Seattle Cancer Care Alliance)
#2Abby Miske (Seattle Cancer Care Alliance)
Last. Kalyan Banda (UW: University of Washington)H-Index: 3
view all 6 authors...
Abstract null null Background null Anthracycline and taxane-based doublets have largely replaced cyclophosphamide, methotrexate, and fluorouracil (CMF) as preferred regimens in the adjuvant treatment of breast cancer. Metronomic CMF is associated with improved tolerability over anthracycline or taxane-based regimens. Previously, there have been no direct comparisons between taxane-based regimens and CMF. null null null Materials and Methods null We performed a retrospective review of 98 breast c...
Source
#1Katelyn N Seale (UMD: University of Maryland, College Park)
#2K. Tkaczuk (UMD: University of Maryland, College Park)H-Index: 4
Abstract null null Breast cancer management has progressed immensely over the decades, but the disease is still a major source of morbidity and mortality worldwide. Even with enhanced imaging detection and tissue biopsy capabilities, disease can progress on an ineffective treatment before additional information is obtained through standard methods of response evaluation, including the RECIST 1.1 criteria, widely used for assessment of treatment response and benefit from therapy 6 . Circulating b...
Source
#1Maarit Bärlund (UTA: University of Tampere)H-Index: 15
#2Laura Takala (UTA: University of Tampere)
Last. Pirkko-Liisa Kellokumpu-Lehtinen (UTA: University of Tampere)H-Index: 34
view all 4 authors...
Abstract null null Backgroud null The growing number of new breast cancer (BC) patients has indicated an urgent need for better tools to monitor patients. Due to the increasing number of unscheduled patient calls, two digital applications were implemented: a callback application (CA) and a digital cancer follow-up application (CFUA). The aim of this study was to evaluate the implementation and added value of digital applications for healthcare professionals in monitoring BC patients from 2012 to...
Source
#1Elizabeth Sakach (Emory University)
#2Ruth M. O’Regan (UR: University of Rochester)
Last. Xiaoxian Li (Emory University)H-Index: 12
view all 4 authors...
Triple negative breast cancer (TNBC) represents 15% to 20% of all primary breast cancers and is the most aggressive subtype of breast cancer. There has been rapid progress in targeted therapy and biomarker development to identify the optimal treatments for TNBC. To update recent developments, this article comprehensively reviews molecular classification and biomarkers of TNBC and targeted therapy developments in immunotherapy, PARP and AKT pathway inhibitors, antibody-drug conjugates and androge...
Source
#1Nathalie LeVasseurH-Index: 6
#2J. SunH-Index: 1
Last. Tamara ShenkierH-Index: 31
view all 11 authors...
Abstract null null Purpose null The use of the 21-gene Recurrence Score® (RS) assay is emerging in node-positive estrogen receptor (ER)+ HER2-negative breast cancer (BC), particularly as initial data from the RxPONDER trial are now available. We investigated the impact of the RS result on adjuvant treatment decisions in such patients. null null null Patients and Methods null This prospective, multi-center study enrolled patients with ER+, HER2-negative BC and 1-3 positive nodes (microscopic [N1m...
Source
#1Rama Rao Malla (GITAM: Gandhi Institute of Technology and Management)H-Index: 17
#2Rakshmitha Marni (GITAM: Gandhi Institute of Technology and Management)
Last. Pappu Lalitha (GITAM: Gandhi Institute of Technology and Management)
view all 5 authors...
Abstract null null The microbiome assisted tumor microenvironment (TME) supports the tumors by modulating multiple mechanisms. Recent studies reported that microbiome dysbiosis is the main culprit of immune suppressive phenotypes of TME. Further, it has been documented that immune suppressive stimulate metastatic phenotype in TME via modulating signaling pathways, cell differentiation, and innate immune response. This review aims at providing comprehensive developments in microbiome and breast T...
Source
12345678910
Top fields of study
Cancer
Pathology
Oncology
Metastatic breast cancer
Breast cancer
General surgery
Medicine